The impact of home treatment and self-administration of omalizumab on chronic urticaria.

ABSTRACT:

Background

Patients suffering from Chronic Spontaneous Urticaria (CSU) may be recalcitrant to treatment with high dose second-generation antihistamines. These patients are, according to international guidelines, eligible to treatment with omalizumab. Treatment with omalizumab has proven to be very effective for this group of patients. Until 2018, when the self-administration of omalizumab was approved, patients have had to visit an outpatient clinic to receive the treatment.

Methods

In this study we performed a survey among 75 CSU patients who had changed their treatment from administration at an outpatient clinic to self-administration at home.

Results

None of the patients experienced decreased effect of the treatment with omalizumab, whereas 41.4% reported improved

SUBMITTER: Wiuff AC 

PROVIDER: S-EPMC9731880 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature